Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B

被引：10

作者：

Lampertico, Pietro ^{[1
]}

Vigano, Mauro ^{[1
]}

Facchetti, Floriana ^{[1
]}

Invernizzi, Federica ^{[1
]}

Aroldi, Adriana ^{[2
]}

Lunghi, Giovanna ^{[3
]}

Messa, Pier Giorgio ^{[2
]}

Colombo, Massimo ^{[1
]}

机构：

[1] Univ Milan, AM & A Migliavacca Ctr Liver Dis, Div Gastroenterol 1, Dept Med,Fdn IRCCS Ca Granda Osped Maggiore Polic, Milan, Italy

[2] Univ Milan, Div Nephrol & Dialysis, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

[3] Univ Milan, Div Hyg, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy

来源：

NEPHROLOGY DIALYSIS TRANSPLANTATION | 2011年 / 26卷 / 06期

关键词：

adefovir dipivoxil; hepatitis B virus; lamivudine-resistance; renal transplantation; POSTRENAL TRANSPLANT PATIENTS; RENAL-ALLOGRAFT RECIPIENTS; VIRUS-INFECTION; DIPIVOXIL; SAFETY; REPLICATION; PREDICTION; CREATININE; ENTECAVIR; EFFICACY;

D O I：

10.1093/ndt/gfr174

中图分类号：

R3 [基础医学]; R4 [临床医学];

学科分类号：

1001 ; 1002 ; 100602 ;

摘要：

Background. To assess the long-term effectiveness and safety of adefovir (ADV) plus lamivudine (LMV) in LMV-resistant (R) kidney transplants with chronic hepatitis B, 11 such patients were treated with add-on ADV. Methods. Serum alanine aminotransferase, renal function and serum hepatitis B virus (HBV) DNA levels were assessed every 3 months; ADV mutations were searched for by INNO-LiPA HBV DR v2 assay. Results. During 36 months (12-48), nine patients cleared serum HBV DNA with a 3-year cumulative virological response rate of 88%, without the emergence of ADV mutations. ADV dose was reduced in six patients (55%) showing a decline of creatinine clearance, in the absence of proximal tubulopathy. Conclusions. In LMV-R kidney graft recipients, long-term add-on therapy with ADV is efficacious and safe with timely adaptation of ADV dose.

引用

页码：2037 / 2041

页数：5

共 27 条

[1] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].